A Big Hit But A Small Miss? Lipitor Generic Launched But Ranbaxy’s Caduet Prospects In Doubt As Mylan Storms The Market
This article was originally published in PharmAsia News
A rollercoaster of a week for India’s Ranbaxy ends with yet another mystery – what is the status of its first-to-file applications for Pfizer’s Caduet?
You may also be interested in...
MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India
MUMBAI - Ranbaxy Laboratories said on June 18 that it has settled most of the patent litigations involving Lipitor (atorvastatin) with Pfizer, putting an end to a five-year legal battle between the two companies
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.